Titles

  • Hematologist and Medical Oncologist, CHUM
  • Assistant Professor of Medicine, Department of Medicine, Université de Montréal
  • Medical Director, Therapeutic Innovations Unit, CRCHUM
  • Research member, Institut du cancer de Montréal

Research Angle

  • Drug development
  • Phase I and Phase II clinical studies
  • Melanoma

Recent Publications

  1. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, Lorigan P, R Lupinacci, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi ACJ, Robert C, Suciu S. (2020). Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. doi:10.1001/jamaoncol.2019.5570
  2. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, Lorigan P, R Lupinacci, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.
  3. Antonia S, Balmanoukian A, Brahmer J, Ou SHI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schoffski P, Jager D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabro L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Gupta AK, Angra N, Abdullah S, Khleif SN, Segal NH (2019). Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC. Journal of Thoracic Oncology. Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20.
  4. Hellmann MD, Kim T-W, Lee CB, Goh B-C, Miller WH, Oh D-Y, Jamal R, Chee C-E, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang Y-J, Siu LL, Bendell J (2019). Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann. Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113
  5. Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, Wong P, Routy B (2019). Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology 8: e1568812.

Email address for application

rahima.jamal.chum@ssss.gouv.qc.ca

Biography

Dr. Jamal has a special interest in clinical research, cancer immunotherapy, early clinical trials and melanoma. Her research program focuses on translating discoveries made in basic research into clinical research. Since September 2018, she is the medical director of the CHUM Therapeutic Innovations Unit, a unit dedicated to Phase I and II studies.